{"id":"https://openalex.org/W2102837183","doi":"https://doi.org/10.2174/156802607779941369","title":"COX-2/5-LOX Dual Acting Anti-Inflammatory Drugs in Cancer Chemotherapy","display_name":"COX-2/5-LOX Dual Acting Anti-Inflammatory Drugs in Cancer Chemotherapy","publication_year":2007,"publication_date":"2007-02-01","ids":{"openalex":"https://openalex.org/W2102837183","doi":"https://doi.org/10.2174/156802607779941369","mag":"2102837183","pmid":"https://pubmed.ncbi.nlm.nih.gov/17305571"},"language":"en","primary_location":{"id":"doi:10.2174/156802607779941369","doi":"https://doi.org/10.2174/156802607779941369","is_oa":false,"landing_page_url":"https://doi.org/10.2174/156802607779941369","pdf_url":null,"source":{"id":"https://openalex.org/S107732428","display_name":"Current Topics in Medicinal Chemistry","issn_l":"1568-0266","issn":["1568-0266","1873-4294"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Topics in Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008940287","display_name":"Laurence Goossens","orcid":"https://orcid.org/0000-0001-6961-9491","observed_orcids":["https://orcid.org/0000-0001-6961-9491"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laurence Goossens","raw_affiliation_strings":["Institut de Chimie Pharmaceutique Albert Lespagnol (EA 2692), 3 rue du Professeur Laguesse, F-59000 Lille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut de Chimie Pharmaceutique Albert Lespagnol (EA 2692), 3 rue du Professeur Laguesse, F-59000 Lille, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009384040","display_name":"Nicole Pommery","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicole Pommery","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110008188","display_name":"Jean Pierre Henichart","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jean Pierre Henichart","raw_affiliation_strings":["Institut de Chimie Pharmaceutique Albert Lespagnol (EA 2692), 3 rue du Professeur Laguesse,F-59000 Lille, France.,France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut de Chimie Pharmaceutique Albert Lespagnol (EA 2692), 3 rue du Professeur Laguesse,F-59000 Lille, France.,France","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5110008188"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.5876,"has_fulltext":false,"cited_by_count":56,"citation_normalized_percentile":{"value":0.91970347,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"7","issue":"3","first_page":"283","last_page":"296"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12910","display_name":"Eicosanoids and Hypertension Pharmacology","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cyclooxygenase-2","display_name":"cyclooxygenase-2","score":0.906000018119812},{"id":"https://openalex.org/keywords/5-lipoxygenase","display_name":"5-lipoxygenase","score":0.9800000190734863},{"id":"https://openalex.org/keywords/arachidonic-acid-metabolism","display_name":"arachidonic acid metabolism","score":0.9459999799728394},{"id":"https://openalex.org/keywords/cancer-chemotherapy","display_name":"cancer chemotherapy","score":0.6420000195503235},{"id":"https://openalex.org/keywords/chemoprevention","display_name":"chemoprevention","score":0.9480000138282776},{"id":"https://openalex.org/keywords/polyunsaturated-fatty-acid-metabolism","display_name":"polyunsaturated fatty acid metabolism","score":0.828000009059906},{"id":"https://openalex.org/keywords/downstream-signaling-pathways","display_name":"downstream signaling pathways","score":0.5460000038146973},{"id":"https://openalex.org/keywords/anticancer-drug-design","display_name":"anticancer drug design","score":0.6880000233650208}],"concepts":[{"id":"https://openalex.org/C2779689624","wikidata":"https://www.wikidata.org/wiki/Q410251","display_name":"Cyclooxygenase","level":3,"score":0.6093100905418396},{"id":"https://openalex.org/C2778078955","wikidata":"https://www.wikidata.org/wiki/Q407699","display_name":"Arachidonic acid","level":3,"score":0.5436815619468689},{"id":"https://openalex.org/C2910924620","wikidata":"https://www.wikidata.org/wiki/Q407699","display_name":"Arachidonic acid metabolism","level":4,"score":0.5303863883018494},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.4999217987060547},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.49817514419555664},{"id":"https://openalex.org/C53345823","wikidata":"https://www.wikidata.org/wiki/Q5531554","display_name":"Gene isoform","level":3,"score":0.4726925194263458},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4703536033630371},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4695744216442108},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38797834515571594},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.37890541553497314},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3299776315689087},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.20706576108932495},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.09185624122619629},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.07922056317329407}],"mesh":[{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016859","descriptor_name":"Lipoxygenase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016859","descriptor_name":"Lipoxygenase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D052246","descriptor_name":"Cyclooxygenase 2 Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D052246","descriptor_name":"Cyclooxygenase 2 Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/156802607779941369","doi":"https://doi.org/10.2174/156802607779941369","is_oa":false,"landing_page_url":"https://doi.org/10.2174/156802607779941369","pdf_url":null,"source":{"id":"https://openalex.org/S107732428","display_name":"Current Topics in Medicinal Chemistry","issn_l":"1568-0266","issn":["1568-0266","1873-4294"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Topics in Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:17305571","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17305571","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current topics in medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7153923391","https://openalex.org/W2014785656","https://openalex.org/W2996271242","https://openalex.org/W4387566310","https://openalex.org/W2136801132","https://openalex.org/W2002138692","https://openalex.org/W2128413921","https://openalex.org/W2179144616","https://openalex.org/W1165803158","https://openalex.org/W2518181447"],"abstract_inverted_index":{"Emerging":[0],"reports":[1],"now":[2],"indicate":[3],"alterations":[4],"of":[5,21,43,54,65,75,82,92,94,108,132,140,167,192],"arachidonic":[6],"acid":[7,126],"metabolism":[8],"with":[9,97,189],"carcinogenesis":[10],"and":[11,14,56,100,143,165,176],"many":[12],"COX":[13,95,142],"LOX":[15,98,144],"inhibitors":[16,110],"(used":[17],"for":[18,123],"the":[19,44,63,80,90,106,114,119,138,157,163,190],"treatment":[20],"inflammatory":[22],"diseases)":[23],"are":[24,58],"being":[25],"investigated":[26],"as":[27],"potential":[28],"anticancer":[29],"drugs.":[30],"Results":[31],"from":[32],"clinical":[33],"trials":[34],"seem":[35],"to":[36,60,88,112,117,162,174,177,181,199],"be":[37,105],"encouraging":[38],"but":[39],"a":[40,101,129,204],"better":[41],"knowledge":[42],"dynamic":[45],"balance":[46],"that":[47,184,201],"shifts":[48],"toward":[49],"lipoxygenases":[50],"(and":[51],"different":[52,141],"isoforms":[53,145],"LOXs)":[55],"cyclooxygenase-2":[57],"essential":[59],"progress":[61],"in":[62,147],"design":[64],"new":[66],"drugs":[67,200],"more":[68],"specially":[69],"directed":[70],"on":[71,79,137,153],"chemoprevention":[72],"or":[73,195],"chemotherapy":[74],"human":[76,148,168],"cancers.":[77,169],"So,":[78],"basis":[81],"these":[83],"results,":[84],"it":[85],"seemed":[86],"useful":[87],"study":[89],"advantages":[91],"combination":[93],"inhibitor":[96,99],"next":[102],"step":[103],"will":[104,151,171],"conception":[107],"dual":[109],"able":[111],"induce":[113],"anticarcinogenic":[115],"and/or":[116],"inhibit":[118],"procarcinogenic":[120],"enzymes":[121],"responsible":[122],"polyunsaturated":[124],"fatty":[125],"metabolism.":[127],"After":[128],"rapid":[130],"summary":[131],"some":[133],"recent":[134],"reviews":[135],"published":[136],"involvement":[139],"present":[146],"cells,":[149],"we":[150],"discuss":[152],"cross-talk":[154],"reported":[155],"between":[156],"downstream":[158],"pathways":[159],"which":[160],"contribute":[161],"development":[164],"progression":[166],"This":[170],"lead":[172],"us":[173],"evoke":[175],"justify":[178],"alternative":[179],"strategies":[180],"develop":[182],"agents":[183],"modulate":[185],"multiple":[186],"targets":[187],"simultaneously":[188],"aim":[191],"enhancing":[193],"efficacy":[194],"improving":[196],"safety":[197],"relative":[198],"address":[202],"only":[203],"single":[205],"enzyme.":[206]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}